Showing results (1311-1320 of 1,332) with videos related to

Sort By:
Pageof 134
The Lancet. Oncology|October 16, 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trialThierry Facon, Shaji K Kumar, Torben Plesner, et al.
Lancet (London, England)|December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
The New England Journal of Medicine|May 30, 2019
Daratumumab plus Lenalidomide and Dexamethasone for Untreated MyelomaThierry Facon, Shaji Kumar, Torben Plesner, et al.
Nature Medicine|September 2, 2025
Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trialAngela DeMichele, Amy S Clark, Emily Shea, et al.
Nature Medicine|February 5, 2025
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trialSaad Z Usmani, Thierry Facon, Vania Hungria, et al.
Blood|March 24, 2025
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease ResultsJill Corre, Laure Vincent, Philippe Moreau, et al.
Clinical Proteomics|December 29, 2021
Urine proteomics identifies biomarkers for diabetic kidney disease at different stagesGuanjie Fan, Tongqing Gong, Yuping Lin, et al.
Nature Genetics|January 3, 2025
The highly allo-autopolyploid modern sugarcane genome and very recent allopolyploidization in SaccharumJisen Zhang, Yiying Qi, Xiuting Hua, et al.
NPJ Breast Cancer|November 24, 2025
DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancerElizabeth M Chislock, Tien-Chi Pan, Dhruv Pant, et al.
The New England Journal of Medicine|December 12, 2023
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, et al.
Pageof 134